Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
IPO Year: 2010
Exchange: NASDAQ
Website: codexis.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/19/2024 | Buy → Hold | The Benchmark Company | |
6/3/2024 | $5.00 | Buy | Jefferies |
5/30/2024 | $11.00 | Overweight | Cantor Fitzgerald |
2/29/2024 | Hold → Buy | The Benchmark Company | |
11/7/2023 | Buy → Hold | The Benchmark Company | |
8/7/2023 | $21.00 → $4.00 | Outperform → Market Perform | TD Cowen |
5/9/2023 | Buy → Neutral | H.C. Wainwright | |
3/31/2022 | $35.00 | Overweight | Piper Sandler |
3/2/2022 | Outperform | Cowen | |
11/5/2021 | $33.00 → $38.00 | Buy | HC Wainwright & Co. |
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ Anticipate Entering First Technical Collaboration for ECO Synthesis™ Manufacturing Platform by End of Year REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. "We're pleased that our second quarter revenues are exactly in-line with our expectations. As a result, we are reiterating our 2024 financial guidance and look forward to a strong second half
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for at least 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be
Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotide with ECO Synthesis™ Manufacturing Platform and will Provide Update at TIDES USA Meeting REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. "We are off to a strong start this year with our first quarter financial results, and we are
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available f
Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End of 2026 2024 to Focus on Securing Early Access Customers for ECO Synthesis™ Manufacturing Platform, Launch of Double-stranded RNA Ligase and Return to Growth for Pharmaceutical Manufacturing REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023, and provided a business update. "W
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the ca
Term loan agreement enables Company to accelerate development and enhance commercialization of ECO Synthesis™ manufacturing platform for RNAi therapeutics Financing bolsters cash position and provides additional flexibility on projected runway through positive cash-flow around end of 2026 Codexis management to host conference call today at 4:30 pm ET REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it has entered into a loan facility agreement with an affiliate of Innovatus Capital Partners, LLC (Innovatus) for up to $40 million, including $30 million upfront and access to an additional $10
Company Remains on Track to Demonstrate Gram-Scale Synthesis with ECO Synthesis™ Platform for RNAi Therapeutics Production by End of Year Strong Financial Position Enables Projected Runway to Expected Positive Cash Flow Around End of 2026 Company to Host Virtual ECO Synthesis™ Platform-Focused KOL Event on December 8, 2023, featuring John Maraganore REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced financial results for the third quarter ended September 30, 2023, and provided a business update. "Over the past quarter, we have continued to deliver on our plan to reduce our cash burn and put ourselv
REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the third quarter of 2023 on Thursday, November 2, 2023, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing (877) 705-2976 (domestic) or (201) 689-8798 (international). A telephone replay of the call will be ava
Organization Streamlined to Focus on Continued Advancement and Commercialization of ECO Synthesis™ Platform for RNAi Therapeutics Production Codexis Expects its Pharmaceutical Manufacturing Business to Return to Growth in 2024 Company Reiterates 2023 Product Revenue Guidance and Announces Preliminary Unaudited Revenue for the Second Quarter of 2023 Management to Host Conference Call Today at 4:30 p.m. ET REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that, in alignment with its previously announced strategy to focus resources on programs with the strongest probability of creating significant val
The Benchmark Company downgraded Codexis from Buy to Hold
Jefferies resumed coverage of Codexis with a rating of Buy and set a new price target of $5.00
Cantor Fitzgerald initiated coverage of Codexis with a rating of Overweight and set a new price target of $11.00
The Benchmark Company upgraded Codexis from Hold to Buy
The Benchmark Company downgraded Codexis from Buy to Hold
TD Cowen downgraded Codexis from Outperform to Market Perform and set a new price target of $4.00 from $21.00 previously
H.C. Wainwright downgraded Codexis from Buy to Neutral
Piper Sandler resumed coverage of Codexis with a rating of Overweight and set a new price target of $35.00
Cowen resumed coverage of Codexis with a rating of Outperform
HC Wainwright & Co. reiterated coverage of Codexis with a rating of Buy and set a new price target of $38.00 from $33.00 previously
Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company's investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty.
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Codexis (NASDAQ:CDXS) with a Overweight rating and announces Price Target of $11.
Benchmark analyst Robert Wasserman reiterates Codexis (NASDAQ:CDXS) with a Buy and maintains $9 price target.
Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 52.94 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $17.073 million which beat the analyst consensus estimate of $13.660 million by 24.98 percent. This is a 31.51 percent increase over sales of $12.982 million the same period last year.
Gainers Cardiff Oncology (NASDAQ:CRDF) shares moved upwards by 28.6% to $2.27 during Thursday's after-market session. The company's market cap stands at $101.4 million. As per the press release, Q4 earnings came out today. Kineta (NASDAQ:KA) shares increased by 20.6% to $0.99. The market value of their outstanding shares is at $10.2 million. Burning Rock Biotech (NASDAQ:BNR) stock rose 10.84% to $0.88. The market value of their outstanding shares is at $90.3 million. Y-mAbs Therapeutics (NASDAQ:YMAB) shares moved upwards by 8.68% to $18.15. The market value of their outstanding shares is at $791.7 million. The company's, Q4 earnings came out today. Lucy Scientific Discovery (NASDAQ:LSDI
Benchmark analyst Robert Wasserman upgrades Codexis (NASDAQ:CDXS) from Hold to Buy and announces $9 price target.
8-K - CODEXIS, INC. (0001200375) (Filer)
S-8 - CODEXIS, INC. (0001200375) (Filer)
10-Q - CODEXIS, INC. (0001200375) (Filer)
8-K - CODEXIS, INC. (0001200375) (Filer)
8-K - CODEXIS, INC. (0001200375) (Filer)
EFFECT - CODEXIS, INC. (0001200375) (Filer)
424B5 - CODEXIS, INC. (0001200375) (Filer)
8-K - CODEXIS, INC. (0001200375) (Filer)
S-3 - CODEXIS, INC. (0001200375) (Filer)
10-Q - CODEXIS, INC. (0001200375) (Filer)
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an increase in its cash reserves through capital raises totaling $31 million via the Company's existing at-the-market facility during the quarter ended September 30, 2024. These funds are in addition to the $73.2 million in cash, cash equivalents and investments on hand as of June 30, 2024. In
REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme LLC, part of Maravai LifeSciences, for multiple enzymes in Codexis' life science enzyme portfolio. The agreement includes licenses for the HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes that were in development directed towards genomics and diagnostics applications prior to the Company's strategic shift announced in July 2023. Under the terms of the agreement, Codexis is eligible to receive sales-based royal
REDWOOD CITY, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 4,950 shares of Codexis common stock and (ii) 8,125 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan. The stock options have an exercise price equal to the closing price per share of Codexis' common stock as reported by Nasdaq on the grant date, and vest over four years, with 25 perc
REDWOOD CITY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that management will participate in two upcoming investor conferences. The Cantor Global Healthcare Conference (New York, NY) Tuesday, September 17, 2024, at 11:30 am ET, management will participate in a fireside chat The Craig-Hallum Bioprocessing Conference (Virtual) Thursday, September 19, 2024, at 2:00 pm ET, management will participate in a fireside chat A live webcast of the Cantor fireside chat will be available in the Investor Relations section of the Company's website, http://ir.codexis.com. A replay of the Craig-Hallum fireside chat wi
REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the Company will participate in a presentation and panel discussion at the upcoming RNA Leaders annual meeting, being held September 4-5, 2024, in San Diego, CA. The Company's presentations will focus on the use of enzymes to drive the scalable and cost-effective manufacture of short inhibitory ribonucleic acid (siRNA) duplexes. During a keynote panel presentation, Stefan Lutz, PhD, Codexis Senior Vice President of Research, in addition to other RNA industry leaders, will discuss how the biopharmaceutical industry is developing new solutions to advance
REDWOOD CITY, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 137,950 shares of Codexis common stock and (ii) 27,000 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan. The stock options have an exercise price equal to the closing price per share of Codexis' common stock as reported by Nasdaq on the grant date, and vest over four years, with 25 pe
REDWOOD CITY, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the publication of its inaugural sustainability disclosures detailing the Company's environmental, social, and governance ("ESG") performance for the fiscal year ended December 31, 2023. The disclosures are aligned with guidance provided by the International Financial Reporting Standards' ("IFRS") Sustainability Accounting Standards Board ("SASB"). This marks an important step in Codexis' sustainability journey and bolsters its efforts to provide stakeholders with important disclosures in a clear and standardized manner. As Codexis continues its growth
Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ Anticipate Entering First Technical Collaboration for ECO Synthesis™ Manufacturing Platform by End of Year REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. "We're pleased that our second quarter revenues are exactly in-line with our expectations. As a result, we are reiterating our 2024 financial guidance and look forward to a strong second half
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for at least 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company's investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty. "We're thrilled to place these exciting programs in highly experienced hands at Crosswalk Therapeutics. Since announcing our strategic shift last year, we have executed multiple transactions to monetize our non-core as
SC 13G - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an increase in its cash reserves through capital raises totaling $31 million via the Company's existing at-the-market facility during the quarter ended September 30, 2024. These funds are in addition to the $73.2 million in cash, cash equivalents and investments on hand as of June 30, 2024. In
REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company's Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications. Her deep biotechnology experience includes leadership roles across fermentation-based commercial manufacturing, process development, plant operations and global supply chain management. "We are honored to have Carole join Codexis as the newest member of our Strategic Advisory Board," sa
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company's Strategic Advisory Board (SAB), joining John Maraganore, PhD, the founder and former Chief Executive Officer of Alnylam Pharmaceuticals. This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company's strategic direction, providing critical insights to inform the continued development of Codexis' ECO Synthesis™ manufacturing platform. "We are thrilled to have Masad and Jim lend their decades of experience
REDWOOD CITY, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in life sciences to Codexis. In this role, Mr. Ryali will lead all aspects of the Company's financial operations and will report directly to Dr. Stephen Dilly, President and Chief Executive Officer of Codexis. "I am excited to announce the addition of Sri to Codexis as we continue to build a top executive leadership team with the strategic acumen, operational experience and commercial mindset to deliver on our pr
REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors. "Stewart's deep expertise in gene therapy and demonstrated track record of executive leadership within the biopharmaceutical industry make her a compelling addition as we seek to continue to strengthen the diversity of our Board with a breadth of professional experience, educational background, and viewpoints," said Byron Dorgan, Chair of the Board of Codexis. "In particular, her experience advising publicly traded pharmaceutical and genomic therapy companies will be valuable as we continu
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Margaret ("Meg") Fitzgerald as Chief Legal Officer and General Counsel, effective immediately. In this role, Ms. Fitzgerald will lead the Company's legal and compliance functions and provide strategic guidance to the Board of Directors and executive management team. She will report directly to Dr. Stephen Dilly, President and CEO of Codexis. "Meg is a seasoned legal executive and leader with extensive experience on both routine and complex legal matters," said Dr. Dilly. "Meg brings invaluabl
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with more than three decades of research and development, operations and commercialization expertise across his time with Takeda Pharmaceutical Co., Novavax, Inc. and Merck & Co., Inc. He currently serves as the Chief Executive Officer of National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company, which he co-founded and built, with end-to-end manufacturing and digital s
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad
REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointments of Karen Frechou-Armijo as Senior Vice President, Human Resources and Asli Aras, Ph.D., as Vice President, Corporate Development. Ms. Frechou-Armijo is responsible for continuing to build a world-class human resources team and to expand the Company's talent acquisition and development strategy. Dr. Aras is responsible for driving the advancement and expansion of Codexis' inorganic growth strategy. Both executives join the Company today and report directly to John Nicols, President and CEO of Cod
REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors. Dr. Martinborough has over two decades of drug discovery, research and development expertise in the life sciences industry, notably at Receptos and Receptos-Celgene where she led the Research team from early-stage drug discovery to initial New Drug Application filing, leading eventually to the successful approval of Zeposia® (Ozanimod) for Multiple Sclerosis (MS). She currently serves as Senior Vice President of Research at Escient Phar